285 related articles for article (PubMed ID: 38499647)
1. Targeting the Hippo pathway to prevent radioresistance brain metastases from the lung (Review).
Taylor J; Dubois F; Bergot E; Levallet G
Int J Oncol; 2024 Jul; 65(1):. PubMed ID: 38785155
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
Juan WC; Hong W
Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
[TBL] [Abstract][Full Text] [Related]
3. The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity.
Shimomura T; Miyamura N; Hata S; Miura R; Hirayama J; Nishina H
Biochem Biophys Res Commun; 2014 Jan; 443(3):917-23. PubMed ID: 24380865
[TBL] [Abstract][Full Text] [Related]
4. miR-582-5p Is a Tumor Suppressor microRNA Targeting the Hippo-YAP/TAZ Signaling Pathway in Non-Small Cell Lung Cancer.
Zhu B; V M; Finch-Edmondson M; Lee Y; Wan Y; Sudol M; DasGupta R
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670427
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors.
Holden JK; Cunningham CN
Cancers (Basel); 2018 Mar; 10(3):. PubMed ID: 29558384
[TBL] [Abstract][Full Text] [Related]
6. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
7. Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers.
Liang H; Xu Y; Zhao J; Chen M; Wang M
Cancer Gene Ther; 2024 May; 31(5):652-666. PubMed ID: 38499647
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CXCR4 regulates epithelial mesenchymal transition of NSCLC via the Hippo-YAP signaling pathway.
Zheng CH; Chen XM; Zhang FB; Zhao C; Tu SS
Cell Biol Int; 2018 Sep; 42(10):1386-1394. PubMed ID: 29972256
[TBL] [Abstract][Full Text] [Related]
9. Long noncoding RNA NSCLCAT1 increases non-small cell lung cancer cell invasion and migration through the Hippo signaling pathway by interacting with CDH1.
Zhao W; Zhang LN; Wang XL; Zhang J; Yu HX
FASEB J; 2019 Jan; 33(1):1151-1166. PubMed ID: 30148675
[TBL] [Abstract][Full Text] [Related]
10. ANKHD1 promotes proliferation and invasion of non‑small‑cell lung cancer cells via regulating YAP oncoprotein expression and inactivating the Hippo pathway.
Liu XF; Han Q; Rong XZ; Yang M; Han YC; Yu JH; Lin XY
Int J Oncol; 2020 May; 56(5):1175-1185. PubMed ID: 32319569
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).
Hsu PC; Jablons DM; Yang CT; You L
Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31387256
[TBL] [Abstract][Full Text] [Related]
12. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
[TBL] [Abstract][Full Text] [Related]
13. Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.
Haderk F; Chou YT; Cech L; Fernández-Méndez C; Yu J; Olivas V; Meraz IM; Barbosa Rabago D; Kerr DL; Gomez C; Allegakoen DV; Guan J; Shah KN; Herrington KA; Gbenedio OM; Nanjo S; Majidi M; Tamaki W; Pourmoghadam YK; Rotow JK; McCoach CE; Riess JW; Gutkind JS; Tang TT; Post L; Huang B; Santisteban P; Goodarzi H; Bandyopadhyay S; Kuo CJ; Roose JP; Wu W; Blakely CM; Roth JA; Bivona TG
Nat Commun; 2024 May; 15(1):3741. PubMed ID: 38702301
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the tumor immune microenvironment by the Hippo Pathway: Implications for cancer immunotherapy.
Liu C; Song Y; Li D; Wang B
Int Immunopharmacol; 2023 Sep; 122():110586. PubMed ID: 37393838
[TBL] [Abstract][Full Text] [Related]
15. Insights into recent findings and clinical application of YAP and TAZ in cancer.
Franklin JM; Wu Z; Guan KL
Nat Rev Cancer; 2023 Aug; 23(8):512-525. PubMed ID: 37308716
[TBL] [Abstract][Full Text] [Related]
16. ALK-positive lung cancer: a moving target.
Schneider JL; Lin JJ; Shaw AT
Nat Cancer; 2023 Mar; 4(3):330-343. PubMed ID: 36797503
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological blockade of TEAD-YAP reveals its therapeutic limitation in cancer cells.
Sun Y; Hu L; Tao Z; Jarugumilli GK; Erb H; Singh A; Li Q; Cotton JL; Greninger P; Egan RK; Tony Ip Y; Benes CH; Che J; Mao J; Wu X
Nat Commun; 2022 Nov; 13(1):6744. PubMed ID: 36347861
[TBL] [Abstract][Full Text] [Related]
18. Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.
Yamazoe M; Ozasa H; Tsuji T; Funazo T; Yoshida H; Hashimoto K; Hosoya K; Ogimoto T; Ajimizu H; Yoshida H; Itotani R; Sakamori Y; Kuninaga K; Aoki W; Hirai T
Cancer Sci; 2023 Feb; 114(2):546-560. PubMed ID: 36285485
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
